From Yahoo Finance: 2025-04-24 10:03:00

Sanofi SA reported a first-quarter 2025 operating income of 2.9 billion euros, up 20.1% year over year and 18.7% in constant currency. Sales were 9.89 billion euros, beating the consensus of $9.77 billion, with U.S. sales up 15.4%. The company’s performance was driven by pharma launches, Dupixent, and Lantus, while legacy medicines were lower.

Sales increased by 10.8% year over year and 9.7% on constant currency. Dupixent sales rose 20.3% to 3.5 billion euros, with strong volume growth. Pharma launches increased by 43.8% to 847 million euros, and vaccine sales were up 11.4% to 1.3 billion euros, driven by Beyfortus.

Sanofi confirmed its 2025 guidance, with anticipated sales growth in the mid-to-high single-digit percentage range at CER. The company expects a strong rebound in business EPS with growth at a low double-digit level. Innate Pharma SA reviewed their collaboration agreement with Sanofi, focusing on the development of SAR’514/IPH6401 in autoimmune indications.



Read more at Yahoo Finance: French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit